Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Express Gene Molecular Diagnostics Laboratory Receives Accreditation from the College of American Pathologists

ExpressGene Lab

The Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation to Express Gene Molecular Diagnostics Laboratory (Express Gene Lab), following a comprehensive on-site inspection by CAP inspectors, who are experienced professionals in pathology and laboratory medicine. This accreditation is a testament to Express Gene's adherence to the highest standards of quality and risk management, contributing significantly to enhanced patient outcomes. Express Gene Lab, was informed of this prestigious global recognition and praised for the laboratory's commitment to excellence in its services. Express Gene Lab is now among the elite group of over 8,000 CAP-accredited facilities worldwide. Express Gene Lab Team expressed their enthusiasm: "Achieving CAP accreditation is a monumental milestone for Express Gene Lab. It underscores our dedication to providing the highest quality of laboratory services and our commitment to patient care. This accreditation affirms our relentless pursuit of excellence and our unwavering commitment to the health and safety of our patients." The CAP accreditation process is rigorous, involving detailed scrutiny of the laboratory’s procedures, records, quality control measures, staff qualifications, equipment, facilities, safety protocols, and overall management. This evaluation ensures adherence to the latest best practices in laboratory medicine.. Express Gene Lab takes immense pride in this achievement, which reflects our pathology and laboratory medicine team's hard work and dedication to high-quality patient care. About the College of American Pathologists: The CAP is the world’s largest organization of board-certified pathologists and a leading provider of laboratory accreditation and proficiency testing programs. It serves patients, pathologists, and the public by promoting excellence in pathology and laboratory medicine globally. For more information, visit CAP.org and follow the stories of pathologists making a difference in patient care at yourpathologist.org. Rooted in pathologist expertise, CAP collaborates with laboratories globally to enhance the quality of laboratory medicine, aiming for operational excellence, diagnostic confidence, and superior patient care About Express Gene Molecular Diagnostics Laboratory Express Gene Lab is at the forefront of molecular diagnostics, offering a comprehensive suite of genetic testing services designed to provide insightful and actionable health information. Our state-of-the-art laboratory is equipped with advanced technology to ensure accuracy and reliability across all tests, including pharmacogenomics, cancer risk assessment, neurogenetic disorders, and prenatal screenings. At Express Gene Lab, we are committed to making genetic testing accessible and understandable, empowering individuals and healthcare providers to make informed decisions about health and treatment strategies. Our team of expert geneticists, pathologists, and laboratory technicians work diligently to uphold the highest standards of quality and confidentiality. With a patient-centric approach, we strive to deliver not just results, but also the support and resources needed to navigate genetic health. Express Gene Lab is proud to be an accredited facility by the College of American Pathologists (CAP), reflecting our dedication to excellence in laboratory services. For Press Inquires: AlphaBull (800) 530-0412 www.Pubcowire.com For more information about our services or to request a testing kit, please visit our website www.expressgene.me/collection or contact us directly. Our customer service team is available to answer any questions and assist with your genetic testing needs. At Express Gene Lab, your health is our priority, and we are dedicated to providing you with the highest level of service and care. Contact Details ExpressGene Lab Lab Direct +1 786-250-3419 info@expressgene.us Company Website https://www.expressgene.us

February 27, 2024 12:54 PM Eastern Standard Time

CSD Social Venture Fund and Gallaudet University Present "Holographic Horizons: Bridging the Educational Divide" at SXSW

Communication Service for the Deaf

CSD Social Venture Fund and Gallaudet University have partnered with Proto Inc., to utilize Proto’s “Epic” holoportation technology as a groundbreaking tool in delivering lifelike, interactive American Sign Language (ASL) education for students who are Deaf and hard of hearing. "Deaf education is on the brink of a transformative leap, where geographical, socioeconomic, and communication disparities will no longer be barriers to quality learning," said Rosa Lee Timm, Division President of CSD Social Venture Fund. “Epic allows students to see and interact with remote instructors as if they are present in the same space, making it an inclusive environment that celebrates and nurtures diversity.” The demo and event, “Holographic Horizons: Bridging the Educational Divide” is set to debut at the Southwest (SXSW) festival on March 4th, 2024, led by panelists Rosavetta Jackson, CSD Social Venture Fund Program Manager; Topher Myers, an educational technology expert; and Dr. Laurene E. Simms, a leading voice for inclusive learning. The panelists will discuss how the Epic holoportation device from Proto Inc can serve as a medium for improving educational accessibility, including how it allows for greater clarity of information exchanged in ASL due to its usage of 3D space over more traditional 2D spaces found in video conferencing platforms. Epic’s lack of physical proximity will be highlighted to show how it opens doors to unimaginable use within the realm of universal design in classroom environments, creating far more learning opportunities and accessibility for students affected by inequity and geopolitics. For more information and to register for the event, please visit: https://sxswedu.com About CSD Social Venture Fund Founded in 2017, the CSD Social Venture Fund aims to support Deaf entrepreneurs in creating jobs, breaking down barriers, and serving as positive representations within the Deaf community. By investing in Deaf-owned businesses and providing resources for entrepreneurs, they seek to strengthen the community of Deaf entrepreneurs and, in turn, the Deaf community at large. About Gallaudet University Gallaudet University has been a cornerstone of the deaf and signing community for over 150 years, promoting the intellectual and professional advancement of deaf and hard of hearing individuals through American Sign Language and English. It upholds a proud tradition of research, scholarly activity, and prepares its graduates for careers in a dynamic, technological world. Gallaudet's vision is to be the university of first choice for the most qualified deaf and hard of hearing students globally. Contact Details Communication Service for the Deaf Rosa Lee Timm +1 518-569-1841 svf@csdsvf.com Company Website https://www.csd.org/

February 27, 2024 11:15 AM Eastern Standard Time

Video

PathAI Launches New Pathologist-Centric Features on AISight to Enable Efficient Case Review through Intelligent Case Prioritization and Real-Time Multi-Institutional Collaboration

PathAI

PathAI, Inc., a leading AI-powered precision pathology company, today announced the availability of two new features on the AISight digital pathology image management system – an Intelligent Caselist and AISight Live. AISight is a cloud-based platform that serves as a central hub for case management, image management, and best-in-class artificial intelligence to enable efficient end-to-end digital pathology workflows. The latest AISight enhancements represent PathAI’s ongoing commitment to empowering pathologists with cutting-edge solutions that improve pathology assessment and laboratory operations and lay the groundwork for broader implementation of AI tools in pathology. AISight Live includes a suite of features to optimize real-time collaboration for a variety of use cases, and its Sync view allows users to follow one another as they navigate the slide – providing real-time case review and interaction with users remotely. An AISight Live Participants list allows users to invite other pathologists for ‘over the shoulder’ and multi-headed scope review/consults, live tumor boards, educational seminars and training, and anonymized viewing to mask PHI if necessary. “The AISight Live collaboration suite marks a significant leap in optimizing remote interactions amongst pathologists,” says Eric Walk, PathAI Chief Medical Officer. “This feature holds immense promise in enhancing collaborative efforts, fostering knowledge exchange, driving resident education, and ultimately improving collaboration through efficient and dynamic pathology workflows.” The Intelligent Caselist features an information-rich data table and three filterable charts, providing pathologists and lab personnel a more streamlined view of their case workload, and allowing for embedded AI to assist in case prioritization. “We’re confident that the AISight Live and the Intelligent Caselist features will simplify pathology workflows and speed up the more tedious tasks – such as case prioritization,” said Pete Romanowich, PathAI Vice President of Program Management and Platform Product. “These features will streamline and optimize pathologist workflows, providing pathologists more time to operate at the top of their license and focus their attention where it matters most.” The AISight platform was created with input from hundreds of pathologists from dozens of institutions, and its launch, and enhancements, underpins all the work PathAI does to support pathologists, biopharma partners and those in the academic research community. AISight Live and the Intelligent Caselist are another critical step in PathAI’s quest to improve patient outcomes with AI-powered pathology. PathAI launched AISight as an IMS in September 2023. Many leading anatomic pathology laboratories ranging from reference laboratories, to independent laboratories and academic medical centers are now using AISight. To learn more about AISight, PathAI’s Image Management System, join our next webinar on February 29, for a live demo of the latest AISight enhancements and an overview of our 2024 product roadmap. AISight is For Research Use Only. Not for use in diagnostic procedures. About PathAI PathAI is the only AI-focused technology company to provide comprehensive precision pathology solutions from wet lab services to algorithm deployment for clinical trials and laboratory use. Rigorously trained and validated with data from more than 15 million annotations, its AI-powered models can be leveraged to optimize the analysis of pathology samples to improve efficiency and accuracy of pathology interpretation, as well as to better gauge therapeutic efficacy and accelerate drug development for complex diseases. For more information, please visit www.pathai.com. PathAI is headquartered in Boston, MA, and manages a CAP/CLIA-certified diagnostics clinical laboratory (formerly known as Poplar Healthcare) – one of the country’s largest anatomic pathology labs – in Memphis, TN. For more information, please visit www.pathai.com. Contact Details SVM Public Relations and Marketing Communications Maggie Naples +1 401-490-9700 pathai@svmpr.com Company Website https://www.pathai.com/

February 27, 2024 10:00 AM Eastern Standard Time

Vaping: Know the Truth: Youth Vaping Prevention & Resources to Quit

YourUpdateTV

A video accompanying this announcement is available at: https://youtu.be/LXqBkJ5imDA E-cigarette use remains a public health threat among youth and young adults with more than 2.1 million middle and high schoolers currently using e-cigarettes, according to the 2023 National Youth Tobacco Survey. Nearly one in four students surveyed use e-cigarettes vape every day or nearly daily, underscoring the highly addictive nature of nicotine, which is harmful to developing brains. It doesn’t stop there. A recent study revealed that teen cannabis use has increased by 245% over the past two decades and approximately 15% of high school seniors who have ever used cannabis become daily or near daily users. On February 5th, a media tour was conducted featuring Amy Taylor, Chief of Community Engagement for Truth Initiative and teachers who use the Vaping: Know the truth curriculum. Vaping: Know the truth is a free, comprehensive digital curriculum designed to empower students by giving them the facts about the health dangers of e-cigarettes and providing resources for youth who vape to quit and made available to schools by leading social impact education innovator, EVERFI. Truth Initiative also recently added two new lessons to the Vaping: Know the truth curriculum to equip students with knowledge about the health effects of vaping cannabis. The new cannabis-focused lessons equip students with knowledge regarding cannabis in vaping products, including short- and long-term health effects, consequences, and risks. Since its launch, more than one million students across the country have actively engaged with the curriculum. It is a self-led interactive online course with peer-to-peer instruction. It was developed as part of Truth Initiative’s proven-effective and nationally recognized truth youth public education campaign. In addition to encouraging students to live vape-free lives, Vaping: Know the truth offers resources to help young people who are currently using e-cigarettes to quit through truth’s first-of-its-kind text message youth quit vaping program This is Quitting, which is already helping more than 700,000 youth and young adults on their journeys to quit. The curriculum also has suggested resources available for young people looking to quit cannabis. For more information, visit TRUTHINITIATIVE.ORG/VAPING-CURRICULUM Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

February 26, 2024 12:25 PM Eastern Standard Time

Video

Clearmind Medicine receives Patent Approval in China for treatment of binge behaviours

Clearmind Medicine Inc

Clearmind Medicine Inc CEO Dr. Adi Zuloff-Shani joined Steve Darling from Proactive to announce a significant milestone for the company: the granting of divisional patent approval by the China National Intellectual Property Administration (CNIPA). This latest patent approval solidifies Clearmind's patent protection for its flagship molecule and further establishes its extensive intellectual property (IP) protection in the psychedelic space. Clearmind's IP portfolio now encompasses fifteen utility patent families, including patents and applications with method of use and composition of matter claims. This includes 24 pending patent applications and 27 granted patents in key jurisdictions such as the US, Europe, China, and India. The company's robust IP portfolio positions it as a leader in the development of innovative treatments in the psychedelic field. Dr. Zuloff-Shani provided insights into Clearmind's flagship molecule, MEAI, which has shown promise in reducing the desire to consume alcoholic beverages while inducing a slight euphoric, alcohol-like experience. This treatment targets Alcohol Use Disorder, a prevalent condition characterized by an individual's inability to control their alcohol consumption despite negative consequences. MEAI also holds potential in addressing binge drinking, offering hope for individuals struggling with this harmful addiction. Clearmind plans to commence clinical trials for alcohol use disorder, expand their IP portfolio, and explore M E's potential in treating obesity. With collaborations with esteemed institutions like Johns Hopkins and Yale, Clearmind aims to revolutionize addiction treatment and offer innovative solutions to societal challenges. Stay tuned for their exciting developments in 2024. Contact Details Proactive North America Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com

February 26, 2024 10:37 AM Eastern Standard Time

Video

Cardiff Lexington CEO Alex Cunningham Discusses Healthcare Growth Strategy

Cardiff Lexington Corporation

Cardiff Lexington CEO Alex Cunningham joined Steve Darling from Proactive to discuss the company's transformation into an acquisition-oriented healthcare firm with a focus on orthopedic surgery centers. Cardiff Lexington's revenue primarily stems from bodily injury and general liability insurance coverages, providing insulation from pricing downsides associated with Medicare and Medicaid. Cunningham emphasized the unique accounts receivable structure of the company, along with its focus on uninsured coverages, which contribute to maintaining high collectability rates. He also highlighted the increasing demand for orthopedic services driven by an aging population, positioning Cardiff Lexington for growth in this market. The company's recent financial performance showed significant increases in revenue, net earnings, and assets, reflecting its strategic focus and operational efficiency. Looking ahead to 2024, Cardiff Lexington plans to continue its expansion through acquisitions, market expansion initiatives, and strategic partnerships. Furthermore, Cunningham mentioned the company's plans to release its 10k in early March and pursue an uplift to a major exchange in 2024, with a clear focus on enhancing shareholder value and achieving strategic growth objectives. Contact Details Proactive North America Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com

February 26, 2024 10:32 AM Eastern Standard Time

Video

IQ-AI advances glioblastoma clinical trial, eyes phase two in 2025

IQ-AI Ltd

Dr Jennifer Connelly, MD, the Principal Investigator (PI) of the IQ-AI Limited sponsored phase one clinical trial that is being conducted at the Medical College of Wisconsin, joined Proactive's Stephen Gunnion with a positive update from its treatment for recurring glioblastoma patients. Connelly explained that glioblastoma, the most common malignant brain tumour, significantly impacts brain function, highlighting the importance of clinical trials to improve patient quality of life. The trial, opened nearly two years ago, investigates gallium maltolate, an oral medication showing promise in preclinical studies and animal models for efficacy against tumour cells. This phase focuses on drug tolerance, with patients reporting ease of use compared to traditional treatments and the ability to maintain normal daily activities. An expanded access programme (EAP), also known as compassionate use, has been launched by IA-AI subsidiary Imaging Biometric to allow wider access to gallium maltolate across the country, benefiting patients unable to travel to the Medical College of Wisconsin. The EAP, approved by the FDA, aims to collect additional safety and toxicity data, contributing to the trial's findings and supporting the progression towards a phase two clinical trial. The next milestone, by the end of 2024, involves concluding the phase one trial, determining the maximum tolerated dose, and preparing for the phase two trial slated for 2025, focusing on safety and beginning to evaluate efficacy. Contact Details Proactive UK Proactive UK +44 20 7989 0813 UKEditorial@proactiveinvestors.com

February 26, 2024 09:51 AM Eastern Standard Time

Video

Better Therapeutics Follows Up Wins Including FDA Authorization For AspyreRx In 2023 With Securing FDA Breakthrough Device Designation Targeting Advanced Liver Disease

Benzinga

By Faith Ashmore, Benzinga Researchers, scientists and practitioners in the past few decades have begun to look at healthcare from a more holistic perspective, often challenging traditional medicine. The question on the minds of many is how to integrate holistic medicine into American healthcare – at scale. One company, Better Therapeutics (NASDAQ: BTTX) is doing just that and trying to revolutionize how healthcare providers treat diseases like diabetes, metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). Better Therapeutics is taking a comprehensive approach to address the root causes of these diseases through the development of a novel form of cognitive behavioral therapy (CBT) that it delivers digitally – enabling near-infinite scalability. Its novel form of CBT has been proven to work for the treatment of type 2 diabetes, helping patients make sustainable lifestyle changes by exploring how their thoughts and beliefs impact their actions – and ultimately their health. However, like much of holistic medicine, without proper FDA authorization and established reimbursement pathways this type of treatment is not accessible or affordable for the millions of patients who could benefit from it. Better Therapeutics has officially secured Breakthrough Device Designation for its groundbreaking CBT platform, intended to treat MASH. MASLD affects roughly 25%-30% of adults around the world, with an even higher prevalence of 75% among individuals with type 2 diabetes and up to 90% among those with advanced obesity. MASH, a more advanced form of the disease, affects approximately 20% of the 25% of American adults who have MASLD and is currently one of the leading indications for liver transplants. Despite the growing rates of MASLD and MASH, there are currently no FDA-approved drugs or devices for treatment. Milestones Hit In 2023 This news comes after Better Therapeutics’ LivVita study's results were published in the peer-reviewed journal Gastro Hep Advances, validating the CBT-based approach. The study successfully achieved its primary endpoint of reducing liver fat in just 90 days, along with significant improvements in liver health through key secondary endpoints, without any device-related adverse events. The study is the first of its kind to demonstrate improvements in various markers, such as FibroScan CAP score, MRI-PDFF, weight, ALT and FastTM score. These results suggest that the treatment has significant therapeutic potential for a larger patient population. Additionally, the study reported no device-related adverse events, even in patients with multiple comorbidities and background pharmacotherapy use. In 2023, Better Therapeutics also received FDA Authorization for its first product, AspyreRx TM, to treat adults with type 2 diabetes. AspyreRx underwent rigorous clinical testing – including a large randomized controlled trial – to demonstrate safety and efficacy. Better Therapeutics reports that the trial showed statistically significant and clinically meaningful decreases in blood sugar when compared to a control group receiving the current standard of care. Specifically, over 50% of patients achieved a clinically meaningful response, with those patients experiencing an average drop of 1.3% in blood sugar as measured by HbA1c; this is similar to what is seen in other modern drug trials. In addition, patients who used AspyreRx were also generally healthier: exploratory data revealed a range of cardiometabolic improvements, including blood pressure, body weight, quality of life, mood, safety and lower medication utilization compared to the control group. In September, the company completed enrollment in a real-world evidence program evaluating the long-term effectiveness of AspyreRx in type 2 diabetes. Given the escalating prevalence, soaring costs and growing burden of cardiometabolic diseases, there is a crucial need to revolutionize how we approach their treatment. Better Therapeutics’ revolutionary approach could open doors for physicians and patients who are looking for more effective methods of treatment. While companies like Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) have seen success with diabetes medication, Better Therapeutics’ transformative solution may have the potential to change the trajectory of the disease. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

February 26, 2024 08:15 AM Eastern Standard Time

Immunic reports successful 2023 and prepares for key 2025 milestones

Immunic Inc

Immunic Inc CEO Dr Daniel Vitt joined Proactive's Stephen Gunnion following what he described as a successful 2023. Outlining the company's achievements, Dr Vitt noted the company strengthened its balance sheet by raising up to $240 million. The first tranche of the three tranche private placement is expected to extend the company's cash runway into the third quarter of 2025, beyond important clinical readouts for its Phase 2 study in progressive multiple sclerosis (MS), known as the CALLIPER study, with results anticipated in April 2025. Clinically, Immunic achieved positive results across its portfolio, including its Vidofludimus calcium and IMU-856. Dr Vitt said vidofludimus calcium showed promising phase 2 interim results in 2023, including a significant reduction in NfL biomarkers in patients with progressive MS, indicating its potential as a unique treatment option. IMU-856, targeting gastrointestinal disorders, demonstrated effectiveness in improving gut function in celiac disease patients, with results published in spring 2023. Looking ahead to 2024, he said the focus is on preparing for the CALLIPER study readout in April 2025 and exploring further studies for IMU-856 in additional indications. The company continues discussions with potential pharmaceutical partners for its programs. Contact Details Proactive North America Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com

February 22, 2024 10:59 AM Eastern Standard Time

Video

1 ... 54 55 56 57 58 ... 308